+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P07712(VDR Antibody) at dilution 1/75. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P07712(VDR Antibody) at dilution 1/75. (Original magnification: ×200)    

  
  

**Background of VDR Antibodies**

The vitamin D receptor (VDR) is a nuclear hormone receptor that mediates the genomic effects of vitamin D, regulating calcium homeostasis, bone metabolism, and immune function. VDR antibodies are autoantibodies targeting this receptor, often implicated in autoimmune disorders. Initially identified in studies of hypocalcemic disorders, these antibodies can interfere with VDR signaling, leading to vitamin D resistance and related pathologies.

VDR antibodies are most notably associated with autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis, where dysregulated immune responses may trigger their production. They disrupt vitamin D’s anti-inflammatory and immunomodulatory roles, exacerbating disease progression. In rare cases, VDR antibodies are linked to hereditary vitamin D-resistant rickets (HVDRR), a condition characterized by impaired bone mineralization despite normal vitamin D levels.

Clinically, detection of VDR antibodies aids in diagnosing autoimmune or resistance syndromes, often via ELISA or cell-based assays. Research also explores their role in chronic kidney disease, cancer, and infectious diseases, where altered VDR signaling may influence outcomes. Therapeutic strategies targeting these antibodies remain experimental, though immunosuppressants or vitamin D analogs are sometimes used to mitigate effects.

Overall, VDR antibodies represent a critical intersection of autoimmunity and endocrine dysfunction, offering insights into personalized treatment approaches for vitamin D-related disorders.